全文获取类型
收费全文 | 49007篇 |
免费 | 3120篇 |
国内免费 | 240篇 |
专业分类
耳鼻咽喉 | 500篇 |
儿科学 | 922篇 |
妇产科学 | 628篇 |
基础医学 | 6402篇 |
口腔科学 | 1079篇 |
临床医学 | 5164篇 |
内科学 | 10854篇 |
皮肤病学 | 988篇 |
神经病学 | 5626篇 |
特种医学 | 2498篇 |
外科学 | 8220篇 |
综合类 | 296篇 |
一般理论 | 13篇 |
预防医学 | 2256篇 |
眼科学 | 647篇 |
药学 | 2956篇 |
中国医学 | 69篇 |
肿瘤学 | 3249篇 |
出版年
2023年 | 432篇 |
2022年 | 690篇 |
2021年 | 1411篇 |
2020年 | 840篇 |
2019年 | 1269篇 |
2018年 | 1438篇 |
2017年 | 1123篇 |
2016年 | 1346篇 |
2015年 | 1557篇 |
2014年 | 1967篇 |
2013年 | 2425篇 |
2012年 | 3896篇 |
2011年 | 3924篇 |
2010年 | 2338篇 |
2009年 | 2101篇 |
2008年 | 3349篇 |
2007年 | 3433篇 |
2006年 | 3169篇 |
2005年 | 3117篇 |
2004年 | 2757篇 |
2003年 | 2637篇 |
2002年 | 2375篇 |
2001年 | 439篇 |
2000年 | 335篇 |
1999年 | 399篇 |
1998年 | 478篇 |
1997年 | 361篇 |
1996年 | 286篇 |
1995年 | 223篇 |
1994年 | 219篇 |
1993年 | 164篇 |
1992年 | 145篇 |
1991年 | 137篇 |
1990年 | 100篇 |
1989年 | 90篇 |
1988年 | 99篇 |
1987年 | 66篇 |
1986年 | 77篇 |
1985年 | 73篇 |
1984年 | 108篇 |
1983年 | 82篇 |
1982年 | 77篇 |
1981年 | 59篇 |
1980年 | 55篇 |
1979年 | 48篇 |
1978年 | 47篇 |
1977年 | 51篇 |
1976年 | 48篇 |
1975年 | 48篇 |
1974年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
951.
952.
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02 总被引:1,自引:0,他引:1
Cacoub P Carrat F Bédossa P Lambert J Pénaranda G Perronne C Pol S Halfon P 《Journal of hepatology》2008,48(5):765-773
BACKGROUND/AIMS: To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients. METHODS: Two hundred and seventy-two HIV/HCV patients, nai ve for HCV treatment, underwent liver biopsy [197 (72%) men, 39.9 years, fibrosis stage (Metavir) F1 (25%), F2 (40%), F3 (25%), F4 (10%), median CD4 486/mm(3) and median HIV viral load 3.5log. Fibrotest (FT), Hepascore (HS), Fibrometer (FM), SHASTA, APRI, Forns index, and Fib-4 were tested in order to differentiate patients with mild to moderate fibrosis (F2) and those with advanced fibrosis (F3). The AUROC and the rate of well-classified patients were compared to liver biopsy. RESULTS: FT, HS, and FM were able to stage liver fibrosis in all patients with AUROCs of 0.78, 0.84 and 0.89 for the diagnosis of F2, respectively. The correlation coefficient indexes were 0.37, 0.46 and 0.48, respectively. The rates of well-classified patients were 62%, 68% and 71%, respectively. Fib-4, APRI and the Forn's index were only able to stage 37-61% of patients and showed lower accuracies. Using a combination of FT, HS and FM did not significantly increase the performance of each test. CONCLUSIONS: In HIV/HCV co-infected patients, Fibrometer, Hepascore and Fibrotest outperformed other non-invasive liver fibrosis biomarkers for the prediction of significant liver fibrosis. 相似文献
953.
Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? 总被引:5,自引:0,他引:5
PURPOSE OF REVIEW: Opportunistic infections contribute to morbidity and mortality after myeloablative allogeneic stem cell transplantation. The development of nonmyeloablative or toxicity-reduced conditioning regimens for allogeneic hematopoietic stem cell transplantation might change this picture significantly. These regimens are in general highly immunosuppressive, but effects on myelopoiesis and mucosal toxicities are usually reduced compared with myeloablative hematopoietic stem cell transplantation conditioning regimens. This review summarizes the infectious risks associated with each type of hematopoietic stem cell transplantation conditioning regimen, and presents the results of early clinical studies. RECENT FINDINGS: Although the data are preliminary, the results of recent studies suggest that nonmyeloablative conditioning regimens may decrease the risks of bacterial infections associated with mucosal damage and persistent neutropenia; however, risks for late viral and fungal infections persist during severe graft versus host disease. Results of several case reports and series emphasize that therapeutic outcomes of infections may be improved in patients who receive nonmyeloablative conditioning regimens. SUMMARY: Infectious risks and outcomes after hematopoietic stem cell transplantation appear to be in evolution given the introduction of alternative, nonmyeloablative conditioning regimens. Although infections remain a prominent cause of transplant-related mortality, the timing and types of infections may differ. Further studies are necessary to define appropriate preventative strategies, and to determine whether patients with ongoing infections might benefit from nonmyeloablative hematopoietic stem cell transplantation. 相似文献
954.
Martin Unverdorben René Quaden Christian Werner Peter Bloss Ralf Degenhardt Hanns Ackermann Christian Vallbracht 《Catheterization and cardiovascular interventions》2003,58(1):29-33
An increasing number of centers are reusing PTCA catheters even though manufacturers warrant single use only. This prospective bench laboratory trial addresses the quality of PTCA balloon catheters after up to three resterilization cycles in order to determine whether a larger trial is warranted to discern whether catheters should be reused. Forty PTCA catheters from two different manufacturers (nominal diameters 1.5 and 3.0 mm) were taken from the shelf. An independent institute tested mechanical properties such as burst pressure, nominal diameter, crossing profile, and balloon surface. The crossing profile increased by 22.5%-39.2% with no additional deterioration after repeated sterilizations. The nominal diameter either increased or decreased by a maximum of 47%. In all 1.5 mm balloons, the burst pressure remained above the manufacturers' values, whereas in the 3.0 mm balloons, the value dropped below the rated burst pressure in 40%-50% of the trials. In conclusion, in both catheter types analyzed, reuse was associated with a considerably worse quality, which puts in question their routine clinical use. 相似文献
955.
Mechanisms of right atrial tachycardia occurring late after surgical closure of atrial septal defects 总被引:3,自引:0,他引:3
Magnin-Poull I De Chillou C Miljoen H Andronache M Aliot E 《Journal of cardiovascular electrophysiology》2005,16(7):681-687
Postatriotomy atrial tachycardia ablation. INTRODUCTION: In patients without structural heart disease, the most frequently occurring AT is the common atrial flutter. In patients with repaired congenital heart disease other mechanisms of AT may occur, due to the presence of an atriotomy that can provide a substrate for reentry. The aim of the present study was to identify the mechanisms of atrial tachycardia (AT) occurring late after atrial septum defect (ASD) repair, with the help of a three-dimensional electroanatomical mapping system. METHODS AND RESULTS: Twenty-two consecutive patients presenting with AT underwent complete electroanatomic mapping (CARTO, Biosense Webster, Diamond Bar, CA) of spontaneously occurring and inducible right ATs. Complete maps of 26 ATs were obtained. Three tachycardia mechanisms were identified: single-loop macroreentrant atrial tachycardia (MAT) (n=7), double-loop MAT (n=18), and focal AT (n=1). In all MATs, protected isthmuses were identified as the electrophysiological substrate of the arrhythmia, most frequently the cavotricuspid isthmus (CTI) (n=24), and a gap between the inferior vena cava and a line of double potentials (n=11). A mean number of 13.5+/-2.1 radiofrequency applications were delivered to transect these critical parts of the circuit. During a follow-up of 25+/-16 months the RF ablation was acutely successful in all patients. Thirteen patients (59%) had an early recurrence of MAT and needed an additional ablation procedure. One of those patients needed two additional ablation procedures. CONCLUSIONS: Three-dimensional electroanatomic mapping is useful to identify postsurgical AT mechanisms; the CTI isthmus is involved in 92% MAT, and if the right atrial free wall (RAFW) abnormal tissue related to surgical scar is present this substrate contributes to the MAT circuit. 相似文献
956.
Frank Tacke Kai Fiedler Mario von Depka Tom Luedde Hartmut Hecker Michael P Manns Arnold Ganser Christian Trautwein 《Liver international》2006,26(2):173-181
BACKGROUND/AIMS: Alterations of plasma coagulation factor XIII may contribute to bleeding disorders in patients with liver cirrhosis. As standard clotting tests such as prothrombin time or activated thromboplastin time (aPTT) cannot detect factor XIII deficiency, this may often be overlooked in clinical practice. We aimed to define factor XIII's clinical and prognostic role in chronic liver disease. PATIENTS AND METHODS: Factor XIII activities were assessed among various other parameters in 111 patients with chronic liver diseases during evaluation for liver transplantation in a prospective study. RESULTS: Unlike coagulation factors II, V or VII, factor XIII activity was maintained in the majority of patients with liver cirrhosis. However, although rarely, factor XIII deficiencies (<50%) occurred, especially in Child C cirrhosis. Factor XIII levels correlated with liver's biosynthetic capacity (cholinesterase activity, albumin, total protein) as well as with platelet count, global coagulation tests and other single coagulation factors. Patients reporting a current systemic bleeding tendency at study entry had significantly reduced factor XIII. In a 6-year follow-up, patients with factor XIII<50% had a significantly increased risk of severe upper gastrointestinal bleed, and reduced factor XIII (<50%, 50-75% vs. normal) was associated with increased mortality. CONCLUSIONS: Factor XIII deficiency is rare in patients with liver cirrhosis, but is associated with a clinical bleeding tendency and an unfavorable prognosis for future hemorrhages and survival. 相似文献
957.
Abstract: Aims/Background: The aim of this review was to determine the benefits and adverse effects of propylthiouracil for patients with alcoholic liver disease. Methods: Systematic Cochrane Review of randomised clinical trials. The Cochrane Hepato‐Biliary Controlled Clinical Trials Register, The Cochrane Library, MEDLINE, and full text searches were combined. All analyses were performed according to the intention‐to‐treat method. Only randomised clinical trials studying patients with alcoholic steatosis, alcoholic fibrosis, alcoholic hepatitis and/or alcoholic cirrhosis were included. Interventions encompassed propylthiouracil at any dose versus placebo or no intervention. The trials could be double‐blind, single‐blind or unblinded. Results: Six randomised clinical trials randomising 710 patients demonstrated no significant effects of propylthiouracil versus placebo on mortality (Peto odds ratio (OR) 0.91, 95% confidence interval (CI) 0.59 to 1.40), liver‐related mortality (OR 0.78, CI 0.45 to 1.33), complications to the liver disease (OR 1.14, CI 0.58 to 2.24), and liver histology. Propylthiouracil was associated with a nonsignificant trend toward an increased risk of nonserious adverse events (OR 1.49, CI 0.74 to 2.99) and with the rare occurrence of serious adverse events (leukopenia). Conclusions: This systematic review could not demonstrate any significant effect of propylthiouracil on any clinically important outcomes (mortality, liver‐related mortality, liver complications and liver histology) of patients with alcoholic liver disease. 相似文献
958.
Charan Yerasi Toby Rogers Brian J. Forrestal Brian C. Case Jaffar M. Khan Itsik Ben-Dor Lowell F. Satler Hector M. Garcia-Garcia Jeffrey E. Cohen Hiroto Kitahara Christian Shults Ron Waksman 《JACC: Cardiovascular Interventions》2021,14(11):1169-1180
Transcatheter aortic valve replacement (TAVR) is approved for all patient risk profiles and is an option for all patients irrespective of age. However, patients enrolled in the low- and intermediate-risk trials were in their 70s, and those in the high-risk trials were in their 80s. TAVR has never been systematically tested in young (<65 years), low-risk patients. Unanswered questions remain, including the safety and effectiveness of TAVR in patients with bicuspid aortic valves; future coronary access; durability of transcatheter heart valves; technical considerations for surgical transcatheter heart valve explantation; management of concomitant conditions such as aortopathy, mitral valve disease, and coronary artery disease; and the safety and feasibility of future TAVR-in-TAVR. The authors predict that balancing these questions with patients’ clear preference for less invasive treatment will become common. In this paper, the authors consider each of these questions and discuss risks and benefits of theoretical treatment strategies in the lifetime management of young patients with severe aortic stenosis. 相似文献
959.
960.
Schatz S Turecek PL Fiedler C Zimmermann K Gritsch H Voorberg J Schwarz HP Dorner F Scheiflinger F 《British journal of haematology》2003,123(4):692-695
We constructed factor VIII-heparin cofactor II (FVIII-HCII) hybrid molecules, which are more readily activated by thrombin in vitro than the respective wild-type molecules. The hybrid proteins were tested in a murine model of haemophilia A to investigate their haemostatic efficacy in vivo. Bleeding characteristics, measured using standard tail-tip cutting techniques, were total blood loss, bleeding time and survival rate. FVIII-HCII hybrids were found to be effective in preventing bleeding in FVIII knockout mice. While in vitro experiments showed that the chimaeric molecules had higher haemostatic functions than the wild-type proteins, the variables analysed in vivo were similar for both proteins. 相似文献